MedPath

Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy

Phase 2
Completed
Conditions
Infantile Hemangioma
Interventions
Drug: Placebo
Registration Number
NCT01056341
Lead Sponsor
Pierre Fabre Dermatology
Brief Summary

There is an unsatisfied medical need for a first-line treatment of proliferating IHs with a good benefit/risk profile. Based on the recent findings of encouraging results obtained with propranolol in a series of infants with severe Infantile Hemangioma (IH), propranolol is expected to be of significant benefit in the management of the condition. The present study has been designed to confirm efficacy of propranolol in severe IH by demonstrating superiority over placebo and to document the safety profile of propranolol in this indication.

Detailed Description

Primary objective The primary objective of this study is to identify the appropriate dose and duration of propranolol treatment and demonstrate its superiority over placebo based on the complete/nearly complete resolution of target IH at W24.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
512
Inclusion Criteria
  • Proliferating IH (target hemangioma) requiring systemic therapy anywhere on the body except on the diaper area with largest diameter of at least 1.5 cm
Exclusion Criteria
  • The patient presents with one or more of the following medical conditions: Congenital hemangioma; Kasabach-Merritt syndrome; bronchial asthma; bronchospasm; hypoglycaemia (< 40 mg/dl or at risk); untreated phaeochromocytoma; hypotension (< 50/30 mmHg); second or third degree heart block; cardiogenic shock; metabolic acidosis; bradycardia (< 80 bpm); severe peripheral arterial circulatory disturbances; Raynaud's phenomenon; sick sinus syndrome; uncontrolled heart failure or Prinzmetal's angina; documented PHACES syndrome with central nervous system involvement
  • The patient has previously been treated for IH, including any surgical and/or medical procedures (e.g. laser therapy)

  • The patient is known to have a hypersensitivity to propranolol and/or any other beta-blockers

  • One or more of the following types of IH are present:

    • Life-threatening IH
    • Function-threatening IH (e.g. those causing impairment of vision, respiratory compromise caused by airway lesions, etc.)
    • Ulcerated IH (whatever the localisation) with pain and lack of response to simple wound care measures
  • The patient was born prematurely and has not yet reached his/her term equivalent age (e.g. an infant born 2 months prematurely cannot be included before the age of 2 months)

  • LVEF (left ventricular systolic function) ≤40% and/or cardiomyopathy and/or hereditary arrhythmia disorder

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebo-
Propranolol oral solutionPropranolol-
Primary Outcome Measures
NameTimeMethod
Interim Analysis : Complete/Nearly Complete Resolution of the Target Infantile Hemangioma at Week 24 Compared to Baseline Based on the Intra-patient Blinded Centralized Independent Qualitative Assessments of Week 24 Photographs.6 months
Primary Analysis : Complete/Nearly Complete Resolution of the Target Infantile Hemangioma at W24 Compared to Baseline Based on the Intra-patient Blinded Centralized Independent Qualitative Assessments of W24 Photographs.6 months
Secondary Outcome Measures
NameTimeMethod
Success/Failure Based on the Investigator Qualitative Assessment of Complete Resolution at W48.6 months

Time to first sustained improvement based on centralized qualitative assessments of paired patient-visits

Trial Locations

Locations (59)

Cardinal Glennon Children's Hospital

🇺🇸

St.Louis, Missouri, United States

The Hospital for Sick Children

🇨🇦

Toronto, Canada

Hopital Nord-CHU St Etienne

🇫🇷

St-Etienne, France

Kinderchirurgische Klinik Ludwig-Maximilians-Universität

🇩🇪

München, Germany

I.O.M.C Alfred Rusescu

🇷🇴

Bucharest, Romania

Spitalul de Copii Dr. Victor Gomoiu

🇷🇴

Bucharest, Romania

Children Dermatology

🇨🇿

Brno, Czech Republic

Hospital Nacional Edgardo Rebagliati Martins

🇵🇪

Lima, Peru

Clinic of Dermatovenerology, University

🇨🇿

Prague, Czech Republic

Spitalul Clinic Urgenta pentru Copii Grigore Alexandrescu

🇷🇴

Bucharest, Romania

Heim Pál Gyermekkórház,

🇭🇺

Budapest, Hungary

Medical University - Filatov Pediatric Hospital

🇷🇺

Moscow, Russian Federation

Klinika Chirurgii i Urologii Dzieci i Mlodziezy Akademii Medycznej

🇵🇱

Gdansk, Poland

Medical Pediatric Academy

🇷🇺

St-Peterburg, Russian Federation

Vilnius University Children's Hospital

🇱🇹

Vilnius, Lithuania

Clinica Internacional

🇵🇪

Lima, Peru

Instituto Nacional de Salud del Niño

🇵🇪

Lima, Peru

University Children's Hospital

🇵🇱

Krakow, Poland

Department of Pediatric Surgery and Oncology

🇵🇱

Lodz, Poland

Klinika Onkologii, Centrum Zdrowia Dziecka

🇵🇱

Warszawa, Poland

Spitalul de Urgenta Copii, Louis Turcanu

🇷🇴

Timisoara, Romania

Spitalul Clinic de Urgenta pentu Copii Sf. Maria

🇷🇴

Iasi, Romania

Neonatal Intensive Care Department

🇷🇺

St-Peterburg, Russian Federation

Hôpital Armand Trousseau

🇫🇷

Paris, France

Hôpital Clocheville

🇫🇷

Tours, France

Royal Children's Hospital

🇦🇺

Melbourne, Australia

CHU St.Justine

🇨🇦

Montreal, Canada

Hôpital Pellegrin-Enfants

🇫🇷

Bordeaux, France

Hôpital Archet 2

🇫🇷

Nice, France

State University of NY

🇺🇸

Brooklyn, New York, United States

Sydney Children's Hospital

🇦🇺

Randwick, Australia

Eastern Clinical Research Unit - Box Hill Hospital

🇦🇺

Box Hill, Australia

Hôpital Necker Enfants malades

🇫🇷

Paris, France

CHU Hôtel Dieu

🇫🇷

Nantes, France

Hospital Sant Pau de Barcelona

🇪🇸

Barcelona, Spain

Hôpital Femme Mère Enfant

🇫🇷

Lyon, France

Kinderkrankenhaus Wilhelmstift

🇩🇪

Hamburg, Germany

Hospital Universitario Virgen del Rocio

🇪🇸

Sevilla, Spain

Hopital Robert Debre - Consultation de Dermatologie

🇫🇷

Paris, France

Hospital La Paz

🇪🇸

Madrid, Spain

Universitätsklinikum Freiburg

🇩🇪

Freiburg, Germany

Hospital Infantil de Mexico Federico Gomez

🇲🇽

Mexico CIty, Mexico

University of Bari

🇮🇹

Bari, Italy

Hôpital des enfants

🇫🇷

Toulouse, France

Waikato Clinical Research 2008 Ltd.

🇳🇿

Hamilton, New Zealand

Clinica Dermatologica

🇮🇹

Milano, Italy

Hospital Universitario de Valencia

🇪🇸

Valencia, Spain

Servicio de Dermatologia del Hospital Infantil

🇪🇸

A Coruna, Spain

Universitätsklinikum Schleswig-Holstein

🇩🇪

Kiel, Germany

Hospital Universitario Infantil Niño Jesús

🇪🇸

Madrid, Spain

Auckland Dermatology

🇳🇿

Auckland, New Zealand

University of California

🇺🇸

Irvine, California, United States

Lucile Packard Children's Hospital

🇺🇸

Redwood City, California, United States

Rady Children's Hospital

🇺🇸

San Diego, California, United States

Miami Children's Hospital

🇺🇸

Miami, Florida, United States

Children's Memorial Hospital

🇺🇸

Chicago, Illinois, United States

Oregon Health Sciences University

🇺🇸

Portland, Oregon, United States

Dell Children's Medical center

🇺🇸

Austin, Texas, United States

Seattle Children's Hospital

🇺🇸

Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath